These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33632044)

  • 1. Capturing biologic treatment for IBD in the Swedish Prescribed Drug Register and the Swedish National Patient Register - a validation study.
    Bröms G; Söderling J; Sachs MC; Halfvarson J; ; Myrelid P; Ludvigsson JF; Everhov ÅH; Olén O
    Scand J Gastroenterol; 2021 Apr; 56(4):410-421. PubMed ID: 33632044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
    Jakobsson GL; Sternegård E; Olén O; Myrelid P; Ljung R; Strid H; Halfvarson J; Ludvigsson JF
    Scand J Gastroenterol; 2017 Feb; 52(2):216-221. PubMed ID: 27797278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
    Gisbert JP; Chaparro M
    J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic Use Patterns and Predictors for Non-persistence and Switching of Biologics in Patients with Inflammatory Bowel Disease: A Nationwide Population-Based Study.
    Jung YS; Han M; Park S; Cheon JH
    Dig Dis Sci; 2020 May; 65(5):1436-1444. PubMed ID: 31677070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of drug survival: A cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register.
    Visuri I; Eriksson C; Olén O; Cao Y; Mårdberg E; Grip O; Gustavsson A; Hjortswang H; Karling P; Montgomery S; Myrelid P; ; Ludvigsson JF; Halfvarson J
    Aliment Pharmacol Ther; 2021 Oct; 54(7):931-943. PubMed ID: 34286871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Analysis of 3-Year Persistence With Vedolizumab Compared With Antibodies Against Tumor Necrosis Factor-Alpha in Patients With Inflammatory Bowel Disease in Germany: Retrospective Analysis of a Large Prescription Database.
    Helwig U; Kostev K; Schmidt C
    J Clin Gastroenterol; 2021 Jan; 55(1):e1-e7. PubMed ID: 32011403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Alulis S; Vadstrup K; Borsi A; Nielsen A; Rikke Jørgensen T; Qvist N; Munkholm P
    Scand J Gastroenterol; 2020 Mar; 55(3):265-271. PubMed ID: 32116064
    [No Abstract]   [Full Text] [Related]  

  • 8. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
    AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
    J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonadherence to Biologic Therapies in Inflammatory Bowel Disease.
    Wentworth BJ; Buerlein RCD; Tuskey AG; Overby MA; Smolkin ME; Behm BW
    Inflamm Bowel Dis; 2018 Aug; 24(9):2053-2061. PubMed ID: 29668917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register.
    Ludvigsson JF; Andersson M; Bengtsson J; Eberhardson M; Fagerberg UL; Grip O; Halfvarson J; Hjortswang H; Jäghult S; Karling P; Nordenvall C; Olén O; Olsson M; Rejler M; Strid H; Myrelid P
    Scand J Gastroenterol; 2019 Sep; 54(9):1089-1101. PubMed ID: 31498717
    [No Abstract]   [Full Text] [Related]  

  • 11. Identification of the Most Cost-effective Position of Vedolizumab Among the Available Biologic Drugs for the Treatment of Ulcerative Colitis.
    Scott FI; Luo M; Shah Y; Lasch K; Vajravelu RK; Mamtani R; Fennimore B; Gerich ME; Lewis JD
    J Crohns Colitis; 2020 Jun; 14(5):575-587. PubMed ID: 31901085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients.
    Rao V; Dharia I; Gibilisco J; Kirelik D; Baumgartner S; Negreira K; Chawla K; Dave J; Kallus S; Belfaqeeh OA; Borum ML
    J Natl Med Assoc; 2024 Feb; 116(1):13-15. PubMed ID: 38036315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
    Shrestha S; Olén O; Eriksson C; Everhov ÅH; Myrelid P; Visuri I; Ludvigsson JF; Schoultz I; Montgomery S; Sachs MC; Halfvarson J; ; Olsson M; Hjortswang H; Bengtsson J; Strid H; Andersson M; Jäghult S; Eberhardson M; Nordenvall C; Björk J; Fagerberg UL; Rejler M; Grip O; Karling P; Block M; Angenete E; Hellström PM; Gustavsson A
    Scand J Gastroenterol; 2020 Apr; 55(4):430-435. PubMed ID: 32370571
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world biologic treatment and associated cost in patients with inflammatory bowel disease.
    Brandes A; Groth A; Gottschalk F; Wilke T; Ratsch BA; Orzechowski HD; Fuchs A; Deiters B; Bokemeyer B
    Z Gastroenterol; 2019 Jul; 57(7):843-851. PubMed ID: 31288280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic drugs for inflammatory bowel disease.
    Yanai S; Matsumoto T
    Nihon Rinsho; 2017 Mar; 75(3):403-407. PubMed ID: 30566782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilization of Treat-to-Target Monitoring Colonoscopy After Treatment Initiation in the US-Based Study of a Prospective Adult Research Cohort With Inflammatory Bowel Disease.
    Yang JY; Lund JL; Funk MJ; Hudgens MG; Lewis JD; Kappelman MD;
    Am J Gastroenterol; 2023 Sep; 118(9):1638-1647. PubMed ID: 37053548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis.
    Taneja V; Anand RS; El-Dallal M; Dong J; Desai N; Taneja I; Feuerstein JD
    Inflamm Bowel Dis; 2024 Apr; 30(4):585-593. PubMed ID: 37300512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologics in inflammatory bowel disease: what are the data?
    Côté-Daigneault J; Bouin M; Lahaie R; Colombel JF; Poitras P
    United European Gastroenterol J; 2015 Oct; 3(5):419-28. PubMed ID: 26535119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Bots SJ; Parker CE; Brandse JF; Löwenberg M; Feagan BG; Sandborn WJ; Jairath V; D'Haens G; Vande Casteele N
    BioDrugs; 2021 Nov; 35(6):715-733. PubMed ID: 34797516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.